Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT164a1 and BNT164b1 Vaccines Against Tuberculosis
NCT05547464Phase 2Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Jul 2023
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of BNT164a1, BNT164b1 in Tuberculosis (TB), sponsored by BioNTech SE. Started Jul 2023; status: active, not recruiting.
02
Drugs
BNT164a1BNT164b1
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05547464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547464.